Empagliflozin Tablet

Empagliflozin Tablet

Product Showcase
Empagliflozin Tablet
Empagliflozin Tablet

Information

Empagliflozin Tablet is an oral SGLT-2 inhibitor product for the treatment of type 2 diabetes mellitus. YS Life Science is developing this product as part of its finished dosage form portfolio, supported by in-house API capabilities. The product is being developed in 10 mg and 25 mg strengths, referencing Jardiance® Tablet. By integrating API development and finished dosage form development, YS Life Science aims to provide a reliable and competitive product option for partners seeking high-quality diabetes treatment products. *Key highlights: Oral tablet formulation for type 2 diabetes mellitus 10 mg and 25 mg strengths SGLT-2 inhibitor class Developed with in-house API capability Approved in 2026 Q2 Launch expected in 2026 Q4
YS Life ScienceE21YS Life Science’s highest priority is the top quality of APIs and FDFs. Our products are manufactured in compliance with ICH guidelines and exported worldwide, including the US, EU, and Japan. With approvals from USFDA, European, and Japanese authorities, we ensure strict quality control and regulatory compliance. We are also seeking FDF partners in Southeast Asia for long-term cooperation.

Log in

See all the content and easy-to-use features by logging in or registering!